# US 2026/0060980 A1 · Polymorphs of triazole antifungal compound pc945

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060980 A1
- Document ID: US20260060980A1
- Status: Published application
- Kind: A1
- Application number: 19/359,464
- Filed: 2025-10-15
- Published: 2026-03-05
- Earliest claimed: 2019-12-06
- Assignees: Pulmocide Limited
- Applicants: Pulmocide Limited
- Inventors: Christopher John WALLIS; Gerald STEELE; Suzanne BUTTAR; Osama SULEIMAN; Julian NORTHEN; John MYKYTIUK; Jamie MARSHALL
- Web page: https://patentgrep.com/patent/US20260060980A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61P 31/10: Antimycotics
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention relates to crystalline polymorphic manifestations of a compound of formula (I): and related aspects.

## Claims

### Claim 1

A method of treatment of a subject with a mycosis which comprises administering to said subject an effective amount of 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-N-(4-fluorophenyl) benzamide in a crystalline form wherein the crystalline form is polymorphic Form 1 or polymorphic Form 2.

### Claim 2

A method of prevention or treatment of disease associated with a mycosis in a subject which comprises administering to said subject an effective amount of 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)-3-methyl phenyl)piperazin-1-yl)-N-(4-fluorophenyl)benzamide in a crystalline form wherein the crystalline form is polymorphic Form 1 or polymorphic Form 2.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the crystalline form is polymorphic Form 1, wherein the crystalline form has an X-ray powder diffraction pattern containing seven peaks selected from (±0.2) 7.0, 7.4, 7.9, 18.2, 19.7, 20.8, 24.7 degrees 2-theta, and/or the crystalline form has unit cell dimensions of 16.80 Å, 23.58 Å and 25.58 Å, and α, β and γ angles of 90°.

### Claim 4 (depends on 2)

The method according to claim 2 wherein the crystalline form is polymorphic Form 1, wherein the crystalline form has an X-ray powder diffraction pattern containing seven peaks selected from (±0.2) 7.0, 7.4, 7.9, 18.2, 19.7, 20.8, 24.7 degrees 2-theta, and/or the crystalline form has unit cell dimensions of 16.80 Å, 23.58 Å and 25.58 Å, and α, β and γ angles of 90°.

### Claim 5 (depends on 1)

The method according to claim 1 wherein the crystalline form is polymorphic Form 2, wherein the crystalline form has an X-ray powder diffraction pattern containing six peaks selected from (±0.2) 10.8, 17.0, 20.3, 22.7, 23.9 and 24.3 degrees 2-theta, and/or the crystalline form has unit cell dimensions of 16.81 Å, 5.65 Å and 35.56 Å, and an α angle of 90°, a β angle of 101.54° and a γ angle of 90°.

### Claim 6 (depends on 2)

The method according to claim 2 wherein the crystalline form is polymorphic Form 1, wherein the crystalline form has an X-ray powder diffraction pattern containing six peaks selected from (±0.2) 10.8, 17.0, 20.3, 22.7, 23.9 and 24.3 degrees 2-theta, and/or the crystalline form has unit cell dimensions of 16.81 Å, 5.65 Å and 35.56 Å, and an α angle of 90°, a β angle of 101.54° and a γ angle of 90°.

### Claim 7 (depends on 3)

The method according to claim 3 wherein the mycosis is caused by Aspergillus spp.

### Claim 8 (depends on 4)

The method according to claim 4 wherein the mycosis is caused by Aspergillus spp.

### Claim 9 (depends on 5)

The method according to claim 5 wherein the mycosis is caused by Aspergillus spp.

### Claim 10 (depends on 6)

The method according to claim 6 wherein the mycosis is caused by Aspergillus spp.

### Claim 11 (depends on 3)

The method according to claim 3 wherein the Aspergillus spp. is Aspergillus fumigatus or Aspergillus pullulans especially Aspergillus fumigatus.

### Claim 12 (depends on 4)

The method according to claim 4 wherein the Aspergillus spp. is Aspergillus fumigatus or Aspergillus pullulans especially Aspergillus fumigatus.

### Claim 13 (depends on 5)

The method according to claim 5 wherein the Aspergillus spp. is Aspergillus fumigatus or Aspergillus pullulans especially Aspergillus fumigatus.

### Claim 14 (depends on 6)

The method according to claim 6 wherein the Aspergillus spp. is Aspergillus fumigatus or Aspergillus pullulans especially Aspergillus fumigatus.

### Claim 15 (depends on 3)

The method according to claim 3 wherein the Aspergillus spp. is an azole resistant Aspergillus fumigatus.

### Claim 16 (depends on 4)

The method according to claim 4 wherein the Aspergillus spp. is an azole resistant Aspergillus fumigatus.

### Claim 17 (depends on 5)

The method according to claim 5 wherein the Aspergillus spp. is an azole resistant Aspergillus fumigatus.

### Claim 18 (depends on 6)

The method according to claim 6 wherein the Aspergillus spp. is an azole resistant Aspergillus fumigatus.

### Claim 19 (depends on 3)

The method according to claim 3 wherein the mycosis is caused by Candida spp., e.g. Candida albicans or Candida glabrata; by Rhizopus spp., e.g. Rhizopus oryzae; by Cryptococcus spp., e.g. Cryptococcus neoformans; by Chaetomium spp., e.g. Chaetomium globosum; by Penicillium spp., e.g. Penicillium chrysogenum or by Trichophyton spp., e.g. Trichophyton rubrum.

### Claim 20 (depends on 4)

The method according to claim 4 wherein the mycosis is caused by Candida spp., e.g. Candida albicans or Candida glabrata; by Rhizopus spp., e.g. Rhizopus oryzae; by Cryptococcus spp., e.g. Cryptococcus neoformans; by Chaetomium spp., e.g. Chaetomium globosum; by Penicillium spp., e.g. Penicillium chrysogenum or by Trichophyton spp., e.g. Trichophyton rubrum.

### Claim 21 (depends on 5)

The method according to claim 5 wherein the mycosis is caused by Candida spp., e.g. Candida albicans or Candida glabrata; by Rhizopus spp., e.g. Rhizopus oryzae; by Cryptococcus spp., e.g. Cryptococcus neoformans; by Chaetomium spp., e.g. Chaetomium globosum; by Penicillium spp., e.g. Penicillium chrysogenum or by Trichophyton spp., e.g. Trichophyton rubrum.

### Claim 22 (depends on 6)

The method according to claim 6 wherein the mycosis is caused by Candida spp., e.g. Candida albicans or Candida glabrata; by Rhizopus spp., e.g. Rhizopus oryzae; by Cryptococcus spp., e.g. Cryptococcus neoformans; by Chaetomium spp., e.g. Chaetomium globosum; by Penicillium spp., e.g. Penicillium chrysogenum or by Trichophyton spp., e.g. Trichophyton rubrum.
